Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2020 Aug 20;26(12):2223–2228. doi: 10.1016/j.bbmt.2020.08.017

Table 2.

Treatment-related AEs in 26 relapsed / refractory HL patients receiving lenalidomide maintenance after ASCT, n (%)

Characteristic Grade 1–2 Grade 3 Grade 4 Total Grade 3 and 4
Hematologic
 Anemia 12 (46.2) 2 (7.7) 0 (0) 2 (7.7)
 Neutropenia 8 (30.8) 9 (34.6) 4 (15.4) 13 (50)
 Lymphopenia 9 (34.6) 6 (23.1) 1 (3.8) 7 (26.9)
Thrombocytopenia 10 (38.5) 4 (15.4) 1 (3.8) 5 (19.2)
Non-hematologic
 Fatigue 9 (34.6) 0 (0) 0 (0) 0 (0)
 Elevated AST / ALT 9 (34.6) 1 (3.8) 0 (0) 1 (3.8)
 Infection 7 (26.9) 1 (3.8) 0 (0) 1 (3.8)
 Rash 6 (23.1) 1 (3.8) 0 (0) 1 (3.8)
 Musculoskeletal pain 5 (19.2) 0 (0) 0 (0) 0 (0)
 Creatinine elevation 4 (15.4) 0 (0) 0 (0) 0 (0)
 Cough 4 (15.4) 0 (0) 0 (0) 0 (0)
 Constipation 4 (15.4) 0 (0) 0 (0) 0 (0)
 Psychiatric disturbance 3 (11.5) 0 (0) 0 (0) 0 (0)
 Pulmonary embolism 0 (0) 1 (3.8) 0 (0) 1 (3.8)
 Pancreatitis 0 (0) 1 (3.8) 0 (0) 1 (3.8)
Laboratory
 Low calcium 6 (23.1) 0 (0) 0 (0) 0 (0)
 Low phosphorous 0 (0) 1 (3.8) 0 (0) 1 (3.8)
 Low potassium 4 (15.4) 2 (7.7) 2 (7.7) 4 (15.4)
 Low sodium 3 (11.6) 0 (0) 0 (0) 0 (0)

Table includes all grade 1–2 AEs occurring in at least 10% of patients and all grade ≥3 AEs that occurred in one or more patients. Only AEs determined by the investigators to be at least possibly related to the study drug are displayed.